Company intelligence / Profile preview
Palvella Therapeutics
Wayne, Pennsylvania, United Statespalvellatx.com ↗
- Ownership
- Public · PVLA
- Development stage
- Phase 3
01
Overview
Clinical-stage biopharma advancing QTORIN™ rapamycin through Phase3 SELVA trial (microcystic LMs) and Phase2 TOIVA trial (cutaneous VMs), with potential first FDA-approved therapies for both indications. Recent merger and $78.9M financing extended cash runway into H2-2027[8][3][6].
- Therapeutic areas
- Rare DiseasesDermatology
- Modalities
- Topical gel
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Pieris Pharmaceuticals
04
Financials
- Market cap
- $2.2B
- Total revenue
- $0
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on Palvella Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Palvella Therapeutics.